Abstract
6005 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have